Radiation Time, Dose, and Fractionation in the Treatment of Lung Cancer

2021 ◽  
Author(s):  
David L. Billing ◽  
Andreas Rimner
Keyword(s):  
Lung Cancer ◽  
Radiation Time ◽  
Time Dose

Radiation Time, Dose, and Fractionation in the Treatment of Lung Cancer

2011 ◽  
pp. 129-141
Author(s):  
Daniel Gomez ◽  
Melenda D. Jeter ◽  
Ritsuko Komaki ◽  
James D. Cox
Keyword(s):  
Lung Cancer ◽  
Radiation Time ◽  
Time Dose

Brain relapses in chemotherapy-treated small cell lung cancer: a retrospective review of two time-dose regimens of therapeutic brain irradiation

Lung Cancer ◽  
1996 ◽  
Vol 15 (2) ◽  
pp. 171-181 ◽  
Author(s):  
Flemming Bach ◽  
Jens B. Sørensen ◽  
Lene Adrian ◽  
Henrik Larsen ◽  
Seppo W. Langer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Retrospective Review ◽  
Small Cell ◽  
Small Cell Lung ◽  
Brain Irradiation ◽  
Time Dose

scholarly journals Clinical Outcomes of Extensive Stage Small Cell Lung Cancer Patients Treated With Thoracic Radiotherapy at Different Timing and Fractionation

2020 ◽  
Author(s):  
Jinmin Han ◽  
Chengrui Fu ◽  
Baosheng Li
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Effective Dose ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Dose Fractionation ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Extensive Stage ◽  
Radiation Time

Abstract Objective: The purpose of this study was to assess whether combined thoracic radiotherapy (TRT) on the basis of chemotherapy (ChT) showed promising anti-tumor activity in extensive-stage small cell lung cancer (ES-SCLC), then to explore practice patterns for radiation time and dose/ fractionation and to identify prognostic factors for patients who would benefit from ChT/TRT.Methods: A total of 492 ES-SCLC patients were included from January 2010 to March 2019, of which 244 patients experienced ChT/TRT. Propensity score matching (PSM) was performed to minimize bias between the ChT/TRT and ChT-alone groups. Patients in ChT/TRT group were categorized into four groups based on the number of induction chemotherapy cycles. For effective dose fractionation calculation, we introduced the time-adjusted biological effective dose(tBED). Categorical variables were analyzed with Chi-square tests and Fisher’s exact tests. Survival rates were computed by the Kaplan-Meier method. Multivariate prognostic analysis was performed with Cox proportional hazard models. Results: Patients who received ChT/TRT were associated with improved OS (18.2 vs 10.8 months), PFS (9.0 vs 6.0 months) and LRFS (12.0 vs 6.0 months) before matching, with similar results after matching. In the ChT/TRT group, the median LRFS times for groups based on radiation time were 12.7, 12.0, 12.7, and 9.0 months, respectively. Earlier TRT had a tendency to prolong PFS (median 10.6 vs 9.8 vs 9.1 vs 7.7 months, respectively, p = 0.1095), as was not seen in OS (median 17.6 vs 19.5 vs 17.2 vs 19.1 months, respectively, p = 0.7224). To note, patients within 6 cycles had better LRFS (p = 0.0006). For radiation dose, patients in high-dose group (tBED>50Gy) had worse OS (median 25.9 vs 22.9, p = 0.0484) and PFS (median 12.1 vs 11.2, p=0.0042) in patients with complete response and partial response (CR and PR) to systemic therapy, but the above-mentioned results were not drawn when the population was confined to those receiving standard fractionation with CR and PR. Conclusion: ChT/TRT could improve survival for ES-SCLC patients. We cautiously recommend that TRT should be performed within 6 cycles and receiving hyperfractionated 45Gy in 30 fractions may be a feasible treatment scheme for ES-SCLC patients.

scholarly journals Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Jinmin Han ◽  
Chengrui Fu ◽  
Baosheng Li
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Dose Fractionation ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Free Survival ◽  
Hyperfractionated Radiotherapy ◽  
Extensive Stage ◽  
Radiation Time

Abstract Objective The purpose of this study was to assess whether thoracic radiotherapy (TRT) combined with chemotherapy (CHT) showed promising anti-tumour activity in extensive-stage small cell lung cancer (ES-SCLC), to explore practice patterns for the radiation time and dose/fractionation and to identify prognostic factors for patients who would benefit from CHT/TRT. Methods A total of 492 ES-SCLC patients were included from January 2010 to March 2019, 244 of whom received CHT/TRT. Propensity score matching was performed to minimize bias between the CHT/TRT and CHT-alone groups. Patients in the CHT/TRT group were categorized into four subgroups based on the number of induction CHT cycles. For effective dose fractionation calculations, we introduced the time-adjusted biological effective dose (tBED). Categorical variables were analysed with chi-square tests and Fisher’s exact tests. Kaplan–Meier curves were generated to estimate survival rates using the R-project. Multivariate prognostic analysis was performed with Cox proportional hazards models. Results Patients who received CHT/TRT experienced improved overall survival (OS) (18.1 vs 10.8 months), progression-free survival (PFS) (9.3 vs 6.0 months) and local recurrence-free survival (LRFS) (12.0 vs 6.6 months) before matching, with similar results after matching. In the CHT/TRT group, the median LRFS times for the groups based on the radiation time were 12.7, 12.0, 12.0, and 9.0 months, respectively. Early TRT had a tendency to prolong PFS (median 10.6 vs 9.8 vs 9.0 vs 7.7 months, respectively, p = 0.091) but not OS (median 17.6 vs 19.5 vs 17.2 vs 19.0 months, respectively, p = 0.622). Notably, patients who received TRT within 6 cycles of CHT experienced prolonged LRFS (p = 0.001). Regarding the radiation dose, patients in the high-dose group (tBED > 50 Gy) who achieved complete response and partial response (CR and PR) to systemic therapy had relatively short OS (median 27.1 vs 22.7, p = 0.026) and PFS (median 11.4 vs 11.2, p = 0.032), but the abovementioned results were not obtained after the exclusion of patients who received hyperfractionated radiotherapy (all p > 0.05). Conclusion CHT/TRT could improve survival for ES-SCLC patients. TRT performed within 6 cycles of CHT and hyperfractionated radiotherapy (45 Gy in 30 fractions) may be a feasible treatment scheme for ES-SCLC patients.

scholarly journals Clinical Outcomes of Extensive Stage Small Cell Lung Cancer Patients Treated With Thoracic Radiotherapy at different timing and fractionation

2021 ◽  
Author(s):  
Jinmin Han ◽  
Chengrui Fu ◽  
Baosheng Li
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Effective Dose ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Dose Fractionation ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Extensive Stage ◽  
Radiation Time

Abstract Objective: The purpose of this study was to assess whether combined thoracic radiotherapy (TRT) on the basis of chemotherapy (CHT) showed promising anti-tumor activity in extensive-stage small cell lung cancer (ES-SCLC), then to explore practice patterns for radiation time and dose/ fractionation and to identify prognostic factors for patients who would benefit from CHT/TRT.Methods: A total of 492 ES-SCLC patients were included from January 2010 to March 2019, of which 244 patients experienced CHT/TRT. Propensity score matching (PSM) was performed to minimize bias between the CHT/TRT and CHT-alone groups. Patients in CHT/TRT group were categorized into four groups based on the number of induction CHT cycles. For effective dose fractionation calculation, we introduced the time-adjusted biological effective dose(tBED). Categorical variables were analyzed with Chi-square tests and Fisher’s exact tests. Kaplan-Meier curves were performed to estimate survival rates using R-project. Multivariate prognostic analysis was performed with Cox proportional hazard models. Results: Patients who received CHT/TRT were associated with improved OS (18.2 vs 10.8 months), PFS (9.0 vs 6.0 months) and LRFS (12.0 vs 6.0 months) before matching, with similar results after matching. In the CHT/TRT group, the median LRFS times for groups based on radiation time were 12.7, 12.0, 12.7, and 9.0 months, respectively. Earlier TRT had a tendency to prolong PFS (median 10.6 vs 9.8 vs 9.1 vs 7.7 months, respectively, p =0.109), as was not seen in OS (median 17.6 vs 19.5 vs 17.2 vs 19.1 months, respectively, p = 0.722). To note, patients performed TRT within 6 cycles CHT had better LRFS (p<0.001). For radiation dose, patients in the high-dose group (tBED>50Gy) had relatively shorter OS (median 25.9 vs 22.9, p = 0.048) and PFS (median 12.1 vs 11.2, p=0.004) in patients with complete response and partial response (CR and PR) to systemic therapy, but the above-mentioned results were not drawn after the exclusion of patients receiving hyperfractionated radiotherapy (all p>0.05).Conclusion: CHT/TRT could improve survival for ES-SCLC patients. TRT performed within 6 cycles CHT and receiving hyperfractionated 45Gy in 30 fractions may be a feasible treatment scheme for ES-SCLC patients.

The question of irradiation therapy in lung cancer

JAMA ◽  
1966 ◽  
Vol 195 (6) ◽  
pp. 471-475 ◽  
Author(s):  
M. J. Krant
Keyword(s):  
Lung Cancer ◽  
Irradiation Therapy

Surgery for Lung Cancer and the Consequences for the Swallow

2016 ◽  
Vol 1 (13) ◽  
pp. 162-168
Author(s):  
Pippa Hales ◽  
Corinne Mossey-Gaston
Keyword(s):  
Lung Cancer ◽  
Treatment Options ◽  
Vocal Cord Palsy ◽  
Subsequent Treatment ◽  
Physiological Reserve ◽  
Palliative Phase ◽  
And Function ◽  
The Impact ◽  
Swallow Function

Lung cancer is one of the most commonly diagnosed cancers across Northern America and Europe. Treatment options offered are dependent on the type of cancer, the location of the tumor, the staging, and the overall health of the person. When surgery for lung cancer is offered, difficulty swallowing is a potential complication that can have several influencing factors. Surgical interaction with the recurrent laryngeal nerve (RLN) can lead to unilateral vocal cord palsy, altering swallow function and safety. Understanding whether the RLN has been preserved, damaged, or sacrificed is integral to understanding the effect on the swallow and the subsequent treatment options available. There is also the risk of post-surgical reduction of physiological reserve, which can reduce the strength and function of the swallow in addition to any surgery specific complications. As lung cancer has a limited prognosis, the clinician must also factor in the palliative phase, as this can further increase the burden of an already compromised swallow. By understanding the surgery and the implications this may have for the swallow, there is the potential to reduce the impact of post-surgical complications and so improve quality of life (QOL) for people with lung cancer.

Sign in / Sign up

Export Citation Format

Share Document